|
1
|
Hassanipour-Azgomi S,
Mohammadian-Hafshejani A, Ghoncheh M, Towhidi F, Jamehshorani S and
Salehiniya H: Incidence and mortality of prostate cancer and their
relationship with the Human Development Index worldwide. Prostate
Int. 4:118–124. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jin JK, Dayyani F and Gallick GE: Steps in
prostate cancer progression that lead to bone metastasis. Int J
Cancer. 128:2545–2561. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nakazawa M and Kyprianou N:
Epithelial-mesenchymal-transition regulators in prostate cancer:
Androgens and beyond. J Steroid Biochem Mol Biol. 166:84–90. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen YS, Wu MJ, Huang CY, Lin SC, Chuang
TH, Yu CC and Lo JF: CD133/Src axis mediates tumor initiating
property and epithelial-mesenchymal transition of head and neck
cancer. PLoS One. 6:e280532011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shiozawa Y, Berry JE, Eber MR, Jung Y,
Yumoto K, Cackowski FC, Yoon HJ, Parsana P, Mehra R, Wang J, et al:
The marrow niche controls the cancer stem cell phenotype of
disseminated prostate cancer. Oncotarget. 7:41217–41232. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Klonisch T, Wiechec E, Hombach-Klonisch S,
Ande SR, Wesselborg S, Schulze-Osthoff K and Los M: Cancer stem
cell markers in common cancers-therapeutic implications. Trends Mol
Med. 14:450–460. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu C, Yao Z, Jiang Y and Keller ET:
Prostate cancer stem cell biology. Minerva Urol Nefrol. 64:19–33.
2012.PubMed/NCBI
|
|
10
|
Kryczek I, Liu S, Roh M, Vatan L, Szeliga
W, Wei S, Banerjee M, Mao Y, Kotarski J, Wicha MS, et al:
Expression of aldehyde dehydrogenase and CD133 defines ovarian
cancer stem cells. Int J Cancer. 130:29–39. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Colombel M, Eaton CL, Hamdy F, Ricci E,
van der Pluijm G, Cecchini M, Mege-Lechevallier F, Clezardin P and
Thalmann G: Increased expression of putative cancer stem cell
markers in primary prostate cancer is associated with progression
of bone metastases. Prostate. 72:713–720. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shmelkov SV, St Clair R, Lyden D and Rafii
S: AC133/CD133/Prominin-1. Int J Biochem Cell Biol. 37:715–719.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Major AG, Pitty LP and Farah CS: Cancer
stem cell markers in head and neck squamous cell carcinoma. Stem
Cells Int. 2013:3194892013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Collins AT, Berry PA, Hyde C, Stower MJ
and Maitland NJ: Prospective identification of tumorigenic prostate
cancer stem cells. Cancer Res. 65:10946–10951. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moon Y, Kim D, Sohn H and Lim W: Effect of
CD133 overexpression on the epithelial-to-mesenchymal transition in
oral cancer cell lines. Clin Exp Metastasis. 33:487–496. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sanchez-Tillo E, de Barrios O, Siles L,
Cuatrecasas M, Castells A and Postigo A: β-catenin/TCF4 complex
induces the epithelial-to-mesenchymal transition (EMT)-activator
ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci USA.
108:19204–19209. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Arguello F, Baggs RB and Frantz CN: A
murine model of experimental metastasis to bone and bone marrow.
Cancer Res. 48:6876–6881. 1988.PubMed/NCBI
|
|
18
|
Valta MP, Tuomela J, Bjartell A, Valve E,
Väänänen HK and Härkönen P: FGF-8 is involved in bone metastasis of
prostate cancer. Int J Cancer. 123:22–31. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee KH, Ahn EJ, Oh SJ, Kim O, Joo YE, Bae
JA, Yoon S, Ryu HH, Jung S and Kim KK: KITENIN promotes glioma
invasiveness and progression, associated with the induction of EMT
and stemness markers. Oncotarget. 6:3240–3253. 2015.PubMed/NCBI
|
|
20
|
Xu MH, Gao X, Luo D, Zhou XD, Xiong W and
Liu GX: EMT and acquisition of stem cell-like properties are
involved in spontaneous formation of tumorigenic hybrids between
lung cancer and bone marrow-derived mesenchymal stem cells. PLoS
One. 9:e878932014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dai J, Hensel J, Wang N, Kruithof-de Julio
M and Shiozawa Y: Mouse models for studying prostate cancer bone
metastasis. Bonekey Rep. 5:7772016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pasqualon T, Lue H, Groening S,
Pruessmeyer J, Jahr H, Denecke B, Bernhagen J and Ludwig A: Cell
surface syndecan-1 contributes to binding and function of
macrophage migration inhibitory factor (MIF) on epithelial tumor
cells. Biochim Biophys Acta. 1863:717–726. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Madeira MF, Queiroz-Junior CM, Costa GM,
Santos PC, Silveira EM, Garlet GP, Cisalpino PS, Teixeira MM, Silva
TA and Souza Dda G: MIF induces osteoclast differentiation and
contributes to progression of periodontal disease in mice. Microbes
Infect. 14:198–206. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Movila A, Ishii T, Albassam A,
Wisitrasameewong W, Howait M, Yamaguchi T, Ruiz-Torruella M,
Bahammam L, Nishimura K, Van Dyke T and Kawai T: Macrophage
migration inhibitory factor (MIF) supports homing of osteoclast
precursors to peripheral osteolytic lesions. J Bone Miner Res.
31:1688–1700. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chu K, Cheng CJ, Ye X, Lee YC, Zurita AJ,
Chen DT, Yu-Lee LY, Zhang S, Yeh ET, Hu MC, et al: Cadherin-11
promotes the metastasis of prostate cancer cells to bone. Mol
Cancer Res. 6:1259–1267. 2008. View Article : Google Scholar : PubMed/NCBI
|
